Repligen Corporation announced that it will restate its financial statements for 2023 and the first half of 2024 due to incorrect revenue recognition related to a $17.3 million COVID-related payment, affecting previously reported revenues but not overall business operations; the updated revenue guidance for 2024 is now between $627 million and $642 million.